AGP Executive Report
Last update: 8 hours agoOncology Research: Poland’s Ryvu Therapeutics and Menarini announced initial clinical activity in a Phase II trial of dapolsertib for heavily pretreated aggressive B-cell lymphoma. More than half of participants had previously received CAR-T therapy; detailed results are due at the ASH meeting on Dec. 13.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.